Last checked at 1 Sep 2020 07:00
1 September 2020 | AIM: RENE |
ReNeuron Group plc
("ReNeuron" or the "Company")
Block Listing Review and Total Voting Rights
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.
Name: | ReNeuron Group plc |
Name of Scheme: | ReNeuron Share Option Schemes |
Period of Return: | From 1 March 2020 to 31 August 2020 |
Balance of unallotted securities under scheme(s) from previous return: | 715,241 Ordinary Shares (of 1p each)
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for): | N/A |
Less: Number of securities issued/allotted under scheme(s) during period | 40,554 |
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 674,687 Ordinary Shares |
Number and class of securities originally admitted and the date of admission: | 20,000 ordinary shares on 13 May 2010 |
Total Voting Rights
At 31 August 2020, the Company had 31,874,324 Ordinary Shares in issue, all with voting rights. This follows the issue of 26,120 new shares arising from the exercise of options by staff, such shares having been admitted under the above block listing arrangement.
As the Company holds no ordinary shares in treasury, the figure of 31,874,324 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.
ENDS
ENQUIRIES:
ReNeuron | +44 (0) 20 3819 8400 |
Olav Hellebø , Chief Executive Officer | |
Michael Hunt, Chief Financial Officer | |
Buchanan (Media/Investor relations) |
+44 (0) 20 7466 5000 |
Mark Court, Tilly Abraham | |
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) Ben Maddison, Stewart Wallace | +44 (0) 20 7710 7600 |
N+1 Singer (Joint Broker) Aubrey Powell, James Moat, Tom Salvesen |
+44 (0) 20 7496 3000 |
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.